Fair point—it’s true that Mesoblast hasn’t been perfect. Like many biotech companies, they’ve faced setbacks in clinical trials, regulatory hurdles, and execution. But that’s part of the journey for any company developing cutting-edge therapies.
What’s different now is that GG’s investment is a turning point. It’s more than just funding. it’s validation from a global leader in pain management, which boosts credibility and market confidence. Combine that with the financial stability GG provides, and it’s clear Mesoblast is in a much stronger position moving forward.
So yes, there’s been some self-inflicted pain in the past, but you can’t overlook how significant GG’s involvement is in helping Mesoblast rise above it.
MSB Price at posting:
$1.88 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)